New York, February 10, 2026, 14:01 EST — Regular session
- AbbVie shares climbed roughly 0.7% in afternoon trading, sticking close to their session peak.
- BNP Paribas Exane bumped up its AbbVie price target to $213, sticking with a neutral rating.
- This week, investors are eyeing delayed U.S. payrolls and inflation numbers, hoping for clues on the next rate move.
AbbVie Inc climbed 0.7% to $224.83 in early afternoon trading Tuesday, sticking near its session peak. Shares moved in a narrow band, fluctuating between $223.00 and $225.78.
AbbVie isn’t making headlines with a huge jump, but even minor fluctuations count for plenty in its part of the market. Investors are left circling the same issue: how does a giant pharma name keep growth on track when rivals and rates won’t stand still?
U.S. stocks split direction: the Dow pushed into new record territory, but the S&P 500 barely budged as investors weighed fresh earnings against a disappointing retail sales report. “The retail sales data is indicating that maybe the economy wasn’t as strong as people expected,” said Charlie Ripley, vice president of portfolio management at Allianz Investment Management. Reuters
BNP Paribas Exane bumped its price target for AbbVie up to $213 from $203 while sticking with a “neutral” rating, MT Newswires said Monday. The price target signals where analysts think the stock might trade in the coming year. MarketScreener
AbbVie projected 2026 adjusted earnings of $14.37 to $14.57 a share last week—excluding certain one-time items—but the stock slipped as Rinvoq’s sales landed below analyst targets. William Blair’s Matt Phipps flagged persistent investor worries about mounting competition in AbbVie’s immunology lineup, pointing to Johnson & Johnson’s Tremfya as a threat. CFO Scott Reents, for his part, highlighted “low-single-digit pricing headwinds” weighing on both Rinvoq and Skyrizi. Reuters
BNP Paribas Exane’s target trails the current share price, a sign the market’s short-term optimism is already reflected. Any wobble now could sting, as the stock is more exposed to shifts in drug demand and pricing.
The setup can turn fast. If Rinvoq’s growth trips up again or pricing pressure bites harder, questions about AbbVie’s pace in replacing legacy cash flows are likely to resurface.
Rate wagers put another twist in the mix. When yields move up, demand for drugmakers with big dividends can take a hit; softer data, on the other hand, usually boosts appetite. That’s one reason pharma stocks often react to big-picture headlines, even if there’s little company-specific news driving the action.
Coming up: the postponed U.S. January payrolls data lands Wednesday, Feb. 11, at 8:30 a.m. ET, followed by January CPI on Friday, Feb. 13, also at 8:30, both pushed back after a short government shutdown shuffled the schedule.
